Trivitron Healthcare in collaboration with Diagon- Vanguard Diagnostics launches Diagon’s Coagulation range in India. Innovative new product introduction in the Coagulation segment to enhance clinical decisions and efficiencies.
New Delhi, 20 October,2021: Trivitron Healthcare, a leading medical devices company has announced the launch of new line of Coagulation Analyzer products manufactured by Diagon Ltd. Trivitron in partnership with Diagon-Vanguard Diagnostics India announced the introduction of these products for the Indian Diagnostics Market following the signing of a collaboration agreement between the companies. This launch augurs well for the medical fraternity as it enhances the efficacies in clinical decision-making and broadens patient management. The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary for reducing bleeding risk in extensive surgeries, checking the efficacy of haemostatic therapies and anti-coagulant drugs.
Commenting on the launch Mr. Rajesh Patel, Chief Executive Officer (IVD Business), Trivitron Healthcare said “Trivitron has prided itself in being the leader in innovation in the clinical and medical technology space. With this launch of product line from Diagon we are looking to broaden the scope and scale of efficacies in patient and clinical management. This range of products will complement Trivitron’s focus on supporting patient management by offering precision in clinical diagnostic fields, such as cardiology, infectious diseases, pathology, biochemistry, as well as inflammatory and autoimmune diseases”.
Commenting on this occasion, Ms. Chandra Ganjoo, Group CPO & Executive Director, Trivitron Healthcare said, “We are expanding and combining our organisational expertise to address the requirements of the medical community by introducing new solutions in the clinical and patient management space. We are proud to announce the enhancement of our IVD range of clinical use by enabling additional products and devices testing menu to our portfolio.”
Commenting on the cooperation agreement Dr. Marco van der Looij, Director of Global Business Development, Diagon Ltd Hungary& Director, Diagon-Vanguard Diagnostics India added, “We are proud to be associated with Trivitron Healthcare that has over 20 years of IVD and medical device manufacturing and selling experience in India. Together with Diagon-Vanguard-Diagnostics India, we will take our presence in the Indian market to a next level by promoting the Diagon COAG haemostasis systems line providing scalable and automated solutions for hospitals and reference laboratories. We are excited we can now offer our next generation haemostasis solutions to all laboratory sectors in India serving needs from POC testing to high-throughput requirements including critical D-Dimer test for COVID-19.”
Commenting on the launch and cooperation agreement Ms. Veena Kohli, Managing Director Diagon Vanguard Diagnostics (P) Limited Indiasaid,
“Diagon-Vanguard Diagnostics India (P) Ltd, a joint venture between long-term partners – Diagon Ltd, and Vanguard Diagnostics (P) Ltd, announces a strategic collaboration with Trivitron Healthcare (P) Ltd. Trivitron will be a channel partner for the world class Coagulation range from Diagon. We are looking forward to jointly serving the Indian market by offering the best solutions in Coagulation, customised to meet the needs of all types of testing set-ups.”
Launching such advanced, accurate, robust technologies and point of care devices in coagulation will help in optical analyses of blood clotting parameters and automation will be a bonus for both lesser and high volume labs. These analyzers are known for their high throughput testing and reagent capacity that help laboratories or settings to increase their efficacy and turnaround time.
The introduced coagulation devices will come with a high throughput for coagulation, chromogenic and immunology tests. Devices are easy-to-use operation with an innovative user interface and built-in QC due to their unique design, features, and multiple applications.
